Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by SAVITRI KRISHNAMURTHY and NAOTO T UENO.
SAVITRI KRISHNAMURTHY
Connection Strength
5.418
NAOTO T UENO
  1. Status of the anaplastic lymphoma kinase (ALK) gene in inflammatory breast carcinoma. Springerplus. 2013; 2:409.
    View in: PubMed
    Score: 0.454
  2. Genomic and transcriptomic analyses identify distinctive features of triple-negative inflammatory breast cancer. NPJ Precis Oncol. 2024 Nov 18; 8(1):265.
    View in: PubMed
    Score: 0.247
  3. Maintenance Pembrolizumab Therapy in Patients with Metastatic HER2-negative Breast Cancer with Prior Response to Chemotherapy. Clin Cancer Res. 2024 Jun 03; 30(11):2424-2432.
    View in: PubMed
    Score: 0.239
  4. EGFR is a master switch between immunosuppressive and immunoactive tumor microenvironment in inflammatory breast cancer. Sci Adv. 2022 12 16; 8(50):eabn7983.
    View in: PubMed
    Score: 0.216
  5. Changes in Triple-Negative Breast Cancer Molecular Subtypes in Patients Without Pathologic Complete Response After Neoadjuvant Systemic Chemotherapy. JCO Precis Oncol. 2022 03; 6:e2000368.
    View in: PubMed
    Score: 0.205
  6. A phase II study of talimogene laherparepvec for patients with inoperable locoregional recurrence of breast cancer. Sci Rep. 2021 11 15; 11(1):22242.
    View in: PubMed
    Score: 0.200
  7. Validation of Prognostic Stage and Anatomic Stage in the American Joint Committee on Cancer 8th Edition for Inflammatory Breast Cancer. Cancers (Basel). 2020 Oct 24; 12(11).
    View in: PubMed
    Score: 0.186
  8. Prognostic Value of HER2 to CEP17 Ratio on Fluorescence In Situ Hybridization Ratio in Patients with Nonmetastatic HER2-Positive Inflammatory and Noninflammatory Breast Cancer Treated with Neoadjuvant Chemotherapy with or without Trastuzumab. Oncologist. 2020 06; 25(6):e909-e919.
    View in: PubMed
    Score: 0.177
  9. Rates of immune cell infiltration in patients with triple-negative breast cancer by molecular subtype. PLoS One. 2018; 13(10):e0204513.
    View in: PubMed
    Score: 0.162
  10. Safety and Efficacy of Panitumumab Plus Neoadjuvant Chemotherapy in Patients With Primary HER2-Negative Inflammatory Breast Cancer. JAMA Oncol. 2018 09 01; 4(9):1207-1213.
    View in: PubMed
    Score: 0.161
  11. International Consensus on the Clinical Management of Inflammatory Breast Cancer from the Morgan Welch Inflammatory Breast Cancer Research Program 10th Anniversary Conference. J Cancer. 2018; 9(8):1437-1447.
    View in: PubMed
    Score: 0.156
  12. Dynamic changes in CD44v-positive cells after preoperative anti-HER2 therapy and its correlation with pathologic complete response in HER2-positive breast cancer. Oncotarget. 2018 Jan 23; 9(6):6872-6882.
    View in: PubMed
    Score: 0.153
  13. Scientific Summary from the Morgan Welch MD Anderson Cancer Center Inflammatory Breast Cancer (IBC) Program 10th Anniversary Conference. J Cancer. 2017; 8(17):3607-3614.
    View in: PubMed
    Score: 0.151
  14. Poor prognosis of patients with triple-negative breast cancer can be stratified by RANK and RANKL dual expression. Breast Cancer Res Treat. 2017 Jul; 164(1):57-67.
    View in: PubMed
    Score: 0.146
  15. Identification of frequent somatic mutations in inflammatory breast cancer. Breast Cancer Res Treat. 2017 Jun; 163(2):263-272.
    View in: PubMed
    Score: 0.145
  16. Erratum to: Overall survival differences between patients with inflammatory and noninflammatory breast cancer presenting with distant metastasis at diagnosis. Breast Cancer Res Treat. 2015 Jul; 152(2):417.
    View in: PubMed
    Score: 0.129
  17. Overall survival differences between patients with inflammatory and noninflammatory breast cancer presenting with distant metastasis at diagnosis. Breast Cancer Res Treat. 2015 Jul; 152(2):407-16.
    View in: PubMed
    Score: 0.128
  18. PEA-15 unphosphorylated at both serine 104 and serine 116 inhibits ovarian cancer cell tumorigenicity and progression through blocking ?-catenin. Oncogenesis. 2012 Jul 16; 1:e22.
    View in: PubMed
    Score: 0.105
  19. MEK1/2 inhibitor selumetinib (AZD6244) inhibits growth of ovarian clear cell carcinoma in a PEA-15-dependent manner in a mouse xenograft model. Mol Cancer Ther. 2012 Feb; 11(2):360-9.
    View in: PubMed
    Score: 0.101
  20. Different gene expressions are associated with the different molecular subtypes of inflammatory breast cancer. Breast Cancer Res Treat. 2011 Feb; 125(3):785-95.
    View in: PubMed
    Score: 0.094
  21. PEA-15 inhibits tumorigenesis in an MDA-MB-468 triple-negative breast cancer xenograft model through increased cytoplasmic localization of activated extracellular signal-regulated kinase. Clin Cancer Res. 2010 Mar 15; 16(6):1802-11.
    View in: PubMed
    Score: 0.089
  22. Epidermal growth factor receptor tyrosine kinase inhibitor reverses mesenchymal to epithelial phenotype and inhibits metastasis in inflammatory breast cancer. Clin Cancer Res. 2009 Nov 01; 15(21):6639-48.
    View in: PubMed
    Score: 0.087
  23. Acquired resistance to erlotinib in A-431 epidermoid cancer cells requires down-regulation of MMAC1/PTEN and up-regulation of phosphorylated Akt. Cancer Res. 2007 Jun 15; 67(12):5779-88.
    View in: PubMed
    Score: 0.074
  24. TGIRT-seq of Inflammatory Breast Cancer Tumor and Blood Samples Reveals Widespread Enhanced Transcription Impacting RNA Splicing and Intronic RNAs in Plasma. medRxiv. 2024 Oct 22.
    View in: PubMed
    Score: 0.061
  25. Correction: Maternal Embryonic Leucine Zipper Kinase Is Associated with Metastasis in Triple-negative Breast Cancer. Cancer Res Commun. 2024 Jan 29; 4(1):236.
    View in: PubMed
    Score: 0.058
  26. Maternal Embryonic Leucine Zipper Kinase is Associated with Metastasis in Triple-negative Breast Cancer. Cancer Res Commun. 2023 06; 3(6):1078-1092.
    View in: PubMed
    Score: 0.056
  27. Stabilization of E-cadherin adhesions by COX-2/GSK3? signaling is a targetable pathway in metastatic breast cancer. JCI Insight. 2023 03 22; 8(6).
    View in: PubMed
    Score: 0.055
  28. Erratum: Ablation of Stromal Cells with a Targeted Proapoptotic Peptide Suppresses Cancer Chemotherapy Resistance and Metastasis. Mol Ther Oncolytics. 2022 Jun 16; 25:305-306.
    View in: PubMed
    Score: 0.052
  29. NDRG1 in Aggressive Breast Cancer Progression and Brain Metastasis. J Natl Cancer Inst. 2022 04 11; 114(4):579-591.
    View in: PubMed
    Score: 0.052
  30. Lipocalin 2 promotes inflammatory breast cancer tumorigenesis and skin invasion. Mol Oncol. 2021 10; 15(10):2752-2765.
    View in: PubMed
    Score: 0.049
  31. Nonphosphorylatable PEA15 mutant inhibits epithelial-mesenchymal transition in triple-negative breast cancer partly through the regulation of IL-8 expression. Breast Cancer Res Treat. 2021 Sep; 189(2):333-345.
    View in: PubMed
    Score: 0.049
  32. Whole-genome sequencing of phenotypically distinct inflammatory breast cancers reveals similar genomic alterations to non-inflammatory breast cancers. Genome Med. 2021 04 26; 13(1):70.
    View in: PubMed
    Score: 0.048
  33. Estrogen Receptor ?-Mediated Inhibition of Actin-Based Cell Migration Suppresses Metastasis of Inflammatory Breast Cancer. Cancer Res. 2021 05 01; 81(9):2399-2414.
    View in: PubMed
    Score: 0.047
  34. Decorin-mediated suppression of tumorigenesis, invasion, and metastasis in inflammatory breast cancer. Commun Biol. 2021 01 15; 4(1):72.
    View in: PubMed
    Score: 0.047
  35. Ablation of Stromal Cells with a Targeted Proapoptotic Peptide Suppresses Cancer Chemotherapy Resistance and Metastasis. Mol Ther Oncolytics. 2020 Sep 25; 18:579-586.
    View in: PubMed
    Score: 0.046
  36. Quantitative hormone receptor (HR) expression and gene expression analysis in HR+ inflammatory breast cancer (IBC) vs non-IBC. BMC Cancer. 2020 May 18; 20(1):430.
    View in: PubMed
    Score: 0.045
  37. The impact of Ki-67 in the context of multidisciplinary care in primary inflammatory breast cancer. J Cancer. 2019; 10(12):2635-2642.
    View in: PubMed
    Score: 0.042
  38. Poor Response to Neoadjuvant Chemotherapy Correlates with Mast Cell Infiltration in Inflammatory Breast Cancer. Cancer Immunol Res. 2019 06; 7(6):1025-1035.
    View in: PubMed
    Score: 0.042
  39. Author Correction: Landscape of somatic mutations in 560 breast cancer whole-genome sequences. Nature. 2019 02; 566(7742):E1.
    View in: PubMed
    Score: 0.041
  40. Distinct epidemiological profiles associated with inflammatory breast cancer (IBC): A comprehensive analysis of the IBC registry at The University of Texas MD Anderson Cancer Center. PLoS One. 2018; 13(9):e0204372.
    View in: PubMed
    Score: 0.040
  41. Decreased expression of microRNA-26b in locally advanced and inflammatory breast cancer. Hum Pathol. 2018 07; 77:121-129.
    View in: PubMed
    Score: 0.039
  42. Prospective Feasibility Trial of Sentinel Lymph Node Biopsy in the Setting of Inflammatory Breast?Cancer. Clin Breast Cancer. 2018 02; 18(1):e73-e77.
    View in: PubMed
    Score: 0.037
  43. 4-1BB-Enhanced Expansion of CD8+ TIL from Triple-Negative Breast Cancer Unveils Mutation-Specific CD8+ T Cells. Cancer Immunol Res. 2017 06; 5(6):439-445.
    View in: PubMed
    Score: 0.037
  44. Cyclin E overexpression as a biomarker for combination treatment strategies in inflammatory breast cancer. Oncotarget. 2017 Feb 28; 8(9):14897-14911.
    View in: PubMed
    Score: 0.036
  45. Towards a transcriptome-based theranostic platform for unfavorable breast cancer phenotypes. Proc Natl Acad Sci U S A. 2016 Nov 08; 113(45):12780-12785.
    View in: PubMed
    Score: 0.035
  46. Histone deacetylase inhibitor-induced cancer stem cells exhibit high pentose phosphate pathway metabolism. Oncotarget. 2016 May 10; 7(19):28329-39.
    View in: PubMed
    Score: 0.034
  47. Landscape of somatic mutations in 560 breast cancer whole-genome sequences. Nature. 2016 06 02; 534(7605):47-54.
    View in: PubMed
    Score: 0.034
  48. miR-141-Mediated Regulation of Brain Metastasis From Breast Cancer. J Natl Cancer Inst. 2016 08; 108(8).
    View in: PubMed
    Score: 0.034
  49. MicroRNA expression profiling identifies decreased expression of miR-205 in inflammatory breast cancer. Mod Pathol. 2016 Apr; 29(4):330-46.
    View in: PubMed
    Score: 0.034
  50. Inflammatory Breast Cancer: A Distinct Clinicopathological Entity Transcending Histological Distinction. PLoS One. 2016; 11(1):e0145534.
    View in: PubMed
    Score: 0.033
  51. Circulating Tumor Cells and Recurrence After Primary Systemic Therapy in Stage III Inflammatory Breast Cancer. J Natl Cancer Inst. 2015 Nov; 107(11).
    View in: PubMed
    Score: 0.033
  52. Inflammation Mediated Metastasis: Immune Induced Epithelial-To-Mesenchymal Transition in Inflammatory Breast Cancer Cells. PLoS One. 2015; 10(7):e0132710.
    View in: PubMed
    Score: 0.032
  53. Outcomes After Multidisciplinary Treatment of Inflammatory Breast Cancer in the Era of Neoadjuvant HER2-directed Therapy. Am J Clin Oncol. 2015 Jun; 38(3):242-7.
    View in: PubMed
    Score: 0.032
  54. Mesenchymal stem cells mediate the clinical phenotype of inflammatory breast cancer in a preclinical model. Breast Cancer Res. 2015 Mar 20; 17:42.
    View in: PubMed
    Score: 0.032
  55. Comparison of molecular subtype distribution in triple-negative inflammatory and non-inflammatory breast cancers. Breast Cancer Res. 2013 Nov 25; 15(6):R112.
    View in: PubMed
    Score: 0.029
  56. The antihelmintic drug pyrvinium pamoate targets aggressive breast cancer. PLoS One. 2013; 8(8):e71508.
    View in: PubMed
    Score: 0.028
  57. Genomic and expression analysis of microdissected inflammatory breast cancer. Breast Cancer Res Treat. 2013 Apr; 138(3):761-72.
    View in: PubMed
    Score: 0.028
  58. Uncovering the molecular secrets of inflammatory breast cancer biology: an integrated analysis of three distinct affymetrix gene expression datasets. Clin Cancer Res. 2013 Sep 01; 19(17):4685-96.
    View in: PubMed
    Score: 0.027
  59. Histone deacetylase inhibitors stimulate dedifferentiation of human breast cancer cells through WNT/?-catenin signaling. Stem Cells. 2012 Nov; 30(11):2366-77.
    View in: PubMed
    Score: 0.027
  60. Inflammatory breast cancer: what we know and what we need to learn. Oncologist. 2012; 17(7):891-9.
    View in: PubMed
    Score: 0.026
  61. Triple-negative subtype predicts poor overall survival and high locoregional relapse in inflammatory breast cancer. Oncologist. 2011; 16(12):1675-83.
    View in: PubMed
    Score: 0.025
  62. Inflammatory breast cancer: the disease, the biology, the treatment. CA Cancer J Clin. 2010 Nov-Dec; 60(6):351-75.
    View in: PubMed
    Score: 0.023
  63. Characterizing cancer cells with cancer stem cell-like features in 293T human embryonic kidney cells. Mol Cancer. 2010 Jul 08; 9:180.
    View in: PubMed
    Score: 0.023
  64. International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment. Ann Oncol. 2011 Mar; 22(3):515-523.
    View in: PubMed
    Score: 0.023
  65. Circulating tumor cells and biomarkers: implications for personalized targeted treatments for metastatic breast cancer. Breast J. 2010 May-Jun; 16(3):327-30.
    View in: PubMed
    Score: 0.022
  66. Circulating tumor cells in metastatic breast cancer: biologic staging beyond tumor burden. Clin Breast Cancer. 2007 Feb; 7(6):471-9.
    View in: PubMed
    Score: 0.018
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.